DPP4

How a new drug prototype regenerates lung tissue

Retrieved on: 
Wednesday, April 10, 2024
Mortality, FDA, Idiopathic pulmonary fibrosis, Scripps Research, National library, National academy, Mouse, Cell, Kidney, World Health Organization, ReFrame, Research, IPF, Death, Respiratory disease, Doctor of Philosophy, DPP4, Rest, B cell, Human, COVID-19, Lung, Regenerative medicine, Biology, Heart failure, Clinical trial, Harvard University, Growth, Disease, Chronic obstructive pulmonary disease, Pharmaceutical industry

LA JOLLA, Calif., April 10, 2024 /PRNewswire/ -- Pulmonary diseases are a leading cause of morbidity and mortality worldwide. For many progressive lung diseases like idiopathic pulmonary fibrosis (IPF), a key issue is a low supply of new stem cells to repair and reverse damage. These cells are responsible for regenerating and increasing the growth of healthy tissue—without them, lung function decreases and a range of severe illnesses can take hold.

Key Points: 
  • "We chose the lung because the stem cell population of the lower airway doesn't regenerate as effectively as one ages."
  • However, there currently are no available treatment options that regenerate damaged lung tissue.
  • To see whether existing drug mechanisms could increase growth of lung stem cells, the team turned to ReFRAME , a drug repurposing library built by Calibr-Skaggs.
  • While NZ-97 is a prototype drug, it's chemically similar to CMR316, Calibr-Skagg's drug that will be entering a phase 1 clinical trial in a few months.

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Pharmaceutical, Health, Adrenoleukodystrophy, Patient, Serono, ALD, Plasma, AMN, Patent, Biomarker, Sumitomo Pharma, Diabetes, Merck, SGLT2, Jaguar 3.4 Litre, EPO, Pharmacokinetics, Male, DPP4, Disease, Prescription, Marshal of France, Pioglitazone, European Patent Office, EUR, United States patent law, Merck Serono, VLCFA, Safety, European Patent Convention, JPY, Estonia, Kidney, POC, Pharmaceutical industry, Imeglimin

Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.

Key Points: 
  • Sumitomo Pharma has worked diligently to increase the production and secure inventory capacity to meet this increasing demand.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • Next Financial Press Release: Fourth Quarter 2023 Cash and Revenue update, on February 15, 2024

Prime Therapeutics and Magellan Rx to present three managed care pharmacy research studies at AMCP Nexus

Retrieved on: 
Monday, October 16, 2023
Nexus, Haemophilia, ABR, Bleeding, Weight loss, Cytokine release syndrome, Radiation, Pharmacotherapy, Non-Hodgkin lymphoma, AMCP, Lymphoma, Cancer, Diabetes, Patient, MRX, Therapy, B-cell lymphoma, DPP4, PMPM, Documentation, Canadian Aviation Regulations, CAR, CRS, Pharmacy, Overalls, Doctor of Pharmacy, Research, NHL, Toxic epidermal necrolysis, Nursing, Pharmaceutical industry, Health insurance, Vaccine, Birth control

EAGAN, Minn., Oct. 16, 2023 /PRNewswire/ -- Prime Therapeutics LLC/Magellan Rx Management (Prime/MRx) will present three research studies at the 2023 Academy of Managed Care Pharmacy (AMCP) Nexus event, October 16-19 in Orlando, Fla.

Key Points: 
  • EAGAN, Minn., Oct. 16, 2023 /PRNewswire/ -- Prime Therapeutics LLC / Magellan Rx Management (Prime/MRx) will present three research studies at the 2023 Academy of Managed Care Pharmacy (AMCP) Nexus event , October 16-19 in Orlando, Fla.
    Health outcomes teams from the organization used integrated medical and pharmacy claims data to evaluate real-world drug utilization, managed care pharmacy programs, and associated costs of care for a range of conditions, including diabetes, lymphoma, and hemophilia.
  • This study illustrates the impact of comprehensive hemophilia care and managed care strategies which led to more than $3.7 million in cost avoidance.
  • More information about these presentations can be found on Prime Therapeutics' events page or the AMCP Nexus website .
  • And for further insights on the studies noted above, visit Prime Therapeutics' newsroom .

Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Diabetes, ULF, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, Sumitomo Pharma, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, AMN, IRIS, Scientific communication, United States patent law, SGLT2, VLCFA, EUR, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Imeglimin, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • This recently issued patent provides additional protection through 2041, with the potential for an additional 5 years through patent term extension.

Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, August 30, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, ULF, Senior, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, USD, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, Communication, AMN, IRIS, Scientific communication, Sumitomo Pharma, United States patent law, SGLT2, VLCFA, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Cryptocurrency, Imeglimin, EUR, Euronext

These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.

Key Points: 
  • These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • As of June 30, 2023, cash and cash equivalents were EUR 7.6 million (USD 8.2 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Fractyl Health Announces Clinical Update on Revita® Real World Registry in Germany and Launch of Revita+™ Telehealth Program Combining Behavioral Recommendations with Revita Treatment for Type 2 Diabetes

Retrieved on: 
Tuesday, August 1, 2023
Health, Medical Devices, Diabetes, Telemedicine, Virtual Medicine, General Health, Clinical Trials, Biotechnology, Glycated hemoglobin, Maintenance, Insulin, Partnership, DPP4, Therapy, Weight loss, Type 2 diabetes, Metabolism, Patient, DSM-IV codes, Metformin, Metabolic syndrome, LDL, Recurrence, Disease, Pharmaceutical industry, Medical device, T2D

Fractyl Health, a metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), today announced clinical updates on the Revita Real World Registry in Germany and the launch of a new telehealth program, called Revita+.

Key Points: 
  • Fractyl Health, a metabolic therapeutics company pioneering new approaches to prevent and reverse type 2 diabetes (T2D), today announced clinical updates on the Revita Real World Registry in Germany and the launch of a new telehealth program, called Revita+.
  • Revita+ is a scalable behavioral modification program created to reduce insulin and glucose excursions.
  • "The initial clinical experiences with Revita DMR in Germany are promising and validate the outcomes observed in previous clinical studies," said Professor Martin.
  • Periodic updates on the Revita Registry and real-world clinical outcomes for patients in Germany undergoing Revita treatment will be shared as the study continues to enroll in more sites.

TheracosBio Announces Commercial Availability of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes

Retrieved on: 
Thursday, July 13, 2023
Health, Diabetes, Research, Pharmaceutical, Science, Biotechnology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Dialysis, Gangrene, Pain, Urinary tract infection, A1C, Incidence, Patient, Risk, Insulin, Ulcer, Fasting, Pancreatitis, Diet, Urine, PBC, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, DPP4, Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, EGFR, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Blood, Erythema, Metformin, Swelling, Type, Moyamoya disease, Knee, Blood pressure, Medicine, Infection, Pyelonephritis, Food, Hospital, Fatal, Necrotizing fasciitis, Glomerular filtration rate, Diabetic ketoacidosis, Perineum, Calorie, SGLT2, Ketoacidosis, Acute kidney injury, Nausea, Bexagliflozin, Female, Pharmaceutical industry, Dietary supplement, Meat

BRENZAVVY is not recommended for patients with type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.

Key Points: 
  • BRENZAVVY is not recommended for patients with type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.
  • BRENZAVVY treatment can be initiated in adults with type 2 diabetes with an estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m2.
  • "We are excited to offer Brenzavvy to our patients with diabetes," said Mark Cuban, co-founder of Mark Cuban Cost Plus Drug Company.
  • "TheracosBio is breaking new ground by making this product available to consumers at a transparent, low price.

Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Adrenoleukodystrophy, Prescription, Imeglimin, Adenosine, Plasma, Journal, JPY, Patient, Serono, Merck, POC, Sumitomo Group, Disease, Male, Business development, FY, Pharmacokinetics, Autosomal dominant polycystic kidney disease, American Association for the Study of Liver Diseases, USD, European Commission, Polycystic kidney disease, Kidney International, HIV disease progression rates, Fatty liver disease, ADPKD, FDA, IPF, Safety, Abstract, DPP4, ALD, ODD, JDS, Merck Serono, Biomarker, DSM-IV codes, AMN, Non-U.S. operators of the M60 Patton, IRIS, Sumitomo Pharma, SGLT2, VLCFA, Life Sciences (journal), Regulation of tobacco by the U.S. Food and Drug Administration, Food, Autosome, Pharmaceutical industry, Bank, Management, EUR, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “This quarter we successfully restructured our debt obligations and increased our financial flexibility with a new equity-linked financing with IRIS.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • As of March 31, 2023, cash and cash equivalents were EUR 10.6 million (USD 11.6 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales

Retrieved on: 
Monday, May 15, 2023
Research, Diabetes, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Abstract, DPP4, FY, NASH, Sumitomo Pharma, JDS, Merck Serono, Prescription, Imeglimin, SGLT2, DSM-IV codes, EUR, JPY, Patient, Fatty liver disease, Serono, Merck, Sumitomo Group, Pharmaceutical industry, Video game, Euronext

As a result, for Sumitomo’s FY 2022, TWYMEEG gross sales reached JPY 2.2 billion (EUR 15.0 million)3, exceeding Sumitomo’s most recent FY 2022 forecast4 by 22%.

Key Points: 
  • As a result, for Sumitomo’s FY 2022, TWYMEEG gross sales reached JPY 2.2 billion (EUR 15.0 million)3, exceeding Sumitomo’s most recent FY 2022 forecast4 by 22%.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • As part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of TWYMEEG, independent of the level of sales.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.

Privacy Commissioner’s Office Publishes an Investigation Report on Two Personal Data Breach Incidents of the Registration and Electoral Office

Retrieved on: 
Monday, January 16, 2023
Education, Computer, Master list of Nixon's political opponents, Election Committee (Hong Kong), EC, Culminating project, SMS, Microsoft Excel, Personal data, Awareness, Review, Assistant, Executive, Master, COVID-19, Clerical, Office of the Privacy Commissioner for Personal Data, Office, Information technology, Risk, National Minimum Wage (Enforcement Notices) Act 2003, DPP4, Name, Personal Data Privacy and Security Act of 2009, Magnetic resonance, REO, Privacy, Recurrence, Election, Privacy Commissioner, Workflow, SPO, Private investigator, Mail, Medical device, Rare-earth element, Internet service provider, Risk management, Online shopping
Key Points: